Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus UNIPEN.
OMNIPEN (AMPICILLIN) vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic